Netherlands-based Preceyes BV seems to have taken the lead in the race to develop a robotic platform for retinal surgery as it prepares to demonstrate ...

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class ...

The OIS Index of ophthalmic stocks surged to new highs in August, driven by two of the highest-weighted stocks in the index. The OIS Index ...

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to ...

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’ ...

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies ...